Crewe Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.8K | Hold |
264
| – | – | ﹤0.01% | 686 |
|
|
2026
Q1 | $14.6K | Hold |
264
| – | – | ﹤0.01% | 577 |
|
|
2025
Q4 | $12.9K | Hold |
264
| – | – | ﹤0.01% | 570 |
|
|
2025
Q3 | $11.4K | Sell |
264
-61
| -19% | -$2.38K | ﹤0.01% | 605 |
|
|
2025
Q2 | $12.5K | Buy |
325
+61
| +23% | +$2.33K | ﹤0.01% | 430 |
|
|
2025
Q1 | $10.2K | Hold |
264
| – | – | ﹤0.01% | 424 |
|
|
2024
Q4 | $8.93K | Hold |
264
| – | – | ﹤0.01% | 438 |
|
|
2024
Q3 | $10.8K | Hold |
264
| – | – | ﹤0.01% | 483 |
|
|
2024
Q2 | $10.2K | Hold |
264
| – | – | ﹤0.01% | 688 |
|
|
2024
Q1 | $11.3K | Buy |
+264
| New | +$10.9K | ﹤0.01% | 601 |
|
|
2023
Q4 | – | Sell |
-264
| Closed | -$9.57K | – | 537 |
|
|
2023
Q3 | $9.57K | Hold |
264
| – | – | ﹤0.01% | 247 |
|
|
2023
Q2 | $9.41K | Hold |
264
| – | – | ﹤0.01% | 415 |
|
|
2023
Q1 | $9.39K | Hold |
264
| – | – | ﹤0.01% | 559 |
|
|
2022
Q4 | $9.28K | Hold |
264
| – | – | ﹤0.01% | 563 |
|
|
2022
Q3 | $8K | Hold |
264
| – | – | ﹤0.01% | 726 |
|
|
2022
Q2 | $14K | Hold |
264
| – | – | ﹤0.01% | 516 |
|
|
2022
Q1 | $14K | Hold |
264
| – | – | ﹤0.01% | 332 |
|
|
2021
Q4 | $15K | Hold |
264
| – | – | ﹤0.01% | 288 |
|
|
2021
Q3 | $13K | Hold |
264
| – | – | ﹤0.01% | 243 |
|
|
2021
Q2 | $13K | Hold |
264
| – | – | ﹤0.01% | 256 |
|
|
2021
Q1 | $12K | Hold |
264
| – | – | ﹤0.01% | 264 |
|
|
2020
Q4 | $12K | Sell |
264
-30
| -10% | -$1.38K | ﹤0.01% | 239 |
|
|
2020
Q3 | $14K | Buy |
294
+30
| +11% | +$1.5K | 0.01% | 212 |
|
|
2020
Q2 | $13K | Hold |
264
| – | – | 0.01% | 154 |
|
|
2020
Q1 | $13K | Sell |
264
-54
| -17% | -$2.88K | 0.01% | 135 |
|
|
2019
Q4 | $19K | Buy |
318
+54
| +20% | +$3K | 0.01% | 154 |
|
|
2019
Q3 | $14K | Hold |
264
| – | – | 0.01% | 172 |
|
|
2019
Q2 | $13K | Hold |
264
| – | – | ﹤0.01% | 202 |
|
|
2019
Q1 | $14K | Hold |
264
| – | – | ﹤0.01% | 171 |
|
|
2018
Q4 | $13K | Hold |
264
| – | – | ﹤0.01% | 175 |
|
|
2018
Q3 | $13K | Hold |
264
| – | – | 0.01% | 188 |
|
|
2018
Q2 | $13K | Hold |
264
| – | – | 0.01% | 197 |
|
|
2018
Q1 | $13K | Sell |
264
-199
| -43% | -$9.27K | 0.01% | 209 |
|
|
2017
Q4 | $21K | Buy |
+463
| New | +$21.4K | 0.02% | 190 |
|
Other funds holding GSK
JEST
Crewe Advisors's GSK Position: Q2 2026 in Review
Crewe Advisors held its GSK (GSK) position steady in Q2 2026 at 264 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #686.
Crewe Advisors first reported a position in GSK in Q4 2017 and has held it in 34 quarters since. The position peaked at $21K in Q4 2017. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Crewe Advisors held 264 shares of GSK worth $13.8K as of Q2 2026.
- Crewe Advisors left its GSK share count unchanged in Q2 2026.
- GSK made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #686 holding.
- Crewe Advisors first reported a position in GSK in Q4 2017 and has held it in 34 quarters since.
- Crewe Advisors's GSK position peaked at $21K in Q4 2017.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.